Last updated: February 13, 2026
Market Analysis and Price Projections for NDC 60687-0721
Overview of the Product
NDC 60687-0721 corresponds to Vosevi (sofosbuvir/velpatasvir/voxilaprevir), a hepatitis C virus (HCV) treatment approved by the FDA in 2017. Vosevi targets genotypes 1-6, including post-treatment failures, with a 12-week regimen. The drug is primarily prescribed for patients with prior treatment failure or resistance to direct-acting antivirals (DAAs).
Market Landscape
Patient Population
- Global HCV prevalence: approximately 58 million people (WHO, 2022).
- U.S. diagnosed cases: estimated at 2.4 million (CDC, 2021).
- Treatment-naïve vs. treatment-experienced patients: roughly 60% of diagnosed patients have received prior therapy; the remaining 40% are treatment-naïve.
Competitive Environment
- Key competitors:
- Gilead’s Harvoni (ledipasvir/sofosbuvir)
- Epclusa (sofosbuvir/velpatasvir)
- Mavyret (glecaprevir/pibrentasvir)
- Zepatier (elbasvir/grazoprevir)
Vosevi's niche lies in patients with previous DAA failure, with limited direct alternatives.
Market Penetration Trends
- Vosevi's sales growth initially high but plateaued due to market saturation.
- Post-2019, new prescribing declined as more patients achieved cure and less complex cases moved to generic affordability.
Price Analysis
Wholesale Acquisition Cost (WAC)
- Initial WAC set at approximately $57,000 per 28-day supply in the U.S.
- Treatment duration:
- For Vosevi: 12 weeks (84 days) typically translates to $171,000 per treatment course.
Real-world Pricing
- Net prices after discounts negotiated by payers generally range from $50,000 to $70,000 per course.
- Private insurers and Medicaid often secure additional rebates, reducing real costs for payers.
International Pricing
- Price varies significantly across countries due to pricing negotiations and patent protections.
- In Europe, list prices range from €25,000 to €40,000 per course.
- Patents protect the drug until at least 2027, limiting generic competition.
Market Projections
Short-term Outlook (2023-2025)
- The U.S. market saturation limits new sales growth.
- Estimated annual sales: $350 million to $500 million.
- Growth fueled by treatment of difficult-to-cure populations and expanding licensing in developing countries.
Long-term Outlook (2026-2030)
- Patent expiration expected around 2027.
- Entry of generics could reduce price points by 60-80%, affecting revenue.
- Sales could decline to $100 million to $200 million annually unless new indications or formulations are developed.
Key Drivers Affecting Pricing and Market Share
- Patent expirations: Generics could enter markets starting 2027, impacting brand pricing.
- Pricing regulations: Countries introducing price caps or negotiated discounts could further compress margins.
- New therapies: Ongoing clinical trials may produce next-generation treatments with enhanced efficacy, which could displace Vosevi.
- Access programs: Manufacturer formulary placements and patient assistance programs influence utilization rates.
Risks and Opportunities
- Risks:
- Patent cliff and generic entry.
- Pricing pressures from payers.
- Limited pipeline expansion for resistant HCV strains.
- Opportunities:
- Expanding use in resistant or relapsed cases.
- Licensing deals in low-income regions.
- Potential new formulations (e.g., longer or shorter regimens).
Final Summary
Vosevi’s market prospects remain constrained by high market saturation, pricing pressures, and upcoming patent expiration. Its niche in treating resistant HCV cases sustains moderate revenue streams, but long-term growth depends on pipeline innovation and market access policies.
Key Takeaways
- The initial price of $57,000 per course faces discounts, with actual reimbursed rates below $70,000.
- The drug's peak revenue period is projected to last until patent expiry in 2027.
- Generic competition post-2027 could reduce revenues by 60-80%.
- Global market expansion is limited by pricing negotiations and patent protections.
- Future growth may depend more on treatment of complex populations than new patient volume.
FAQs
Q1: When is patent expiration expected for Vosevi?
A: Patent protection is anticipated to last until 2027, after which generic versions could enter markets.
Q2: How does Vosevi compare in price to its competitors?
A: Its list price mirrors other branded DAA therapies, roughly $57,000 per 28-day supply, but effective prices after discounts are typically 10-15% lower.
Q3: What factors could influence the drug’s market share in the next five years?
A: Patent expiration, introduction of generics, evolving pricing policies, and development of new treatments.
Q4: Are there any licensing or manufacturing opportunities in emerging markets?
A: Yes, licensing deals in countries with limited alternatives and lower price thresholds could expand market reach before patent expiry.
Q5: How might new clinical data affect the drug’s market positioning?
A: Data supporting broader or more effective use could sustain sales longer and justify premium pricing temporarily.
References
[1] World Health Organization (WHO). "Hepatitis C," 2022.
[2] CDC. "Hepatitis C – CDC Fact Sheet," 2021.
[3] IQVIA. "Global Market Insights for Hepatitis C Therapies," 2022.
